Prognostic significance of osteopontin in patients with non-small cell lung cancer: Results from a meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 12765-12773

  Liu, Yang ^a   Gu, Xiaobin ^a   Lin, Qunying ^b   Tian, Tian ^a   Shao, Lijuan ^c   Yuan, Chao ^a   Zhang, Bo ^a,d   Fan, Kexing ^a,d  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PUTIAN UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Non small cell lung cancer; Osteopontin; Prognosis

Indexed keywords

OSTEOPONTIN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 84943544020     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
4. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J and Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4: 792-801.
5. Sodek J, Ganss B and McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279-303.
6. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P and Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011; 15: 1113-1126.
7. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006; 6: 819-830.
8. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M and Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999; 160: 1269-1273.
9. Guldur ME, Kibar Y, Deniz H and Bakir K. Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. Pathol Oncol Res 2010; 16: 55-59.
10. Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY and Shao CK. Expressions of osteopontin (OPN), (alpha)(nu)(beta)3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC). Chin J Cancer Res 2012; 24: 103-108.
11. Yu TT, Han ZG, Shan L, Tao J, Zhang T, Yuan SF and Shen HL. Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev 2014; 15: 29-32.
12. Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F and Fontanini G. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005; 11: 6459-6465.
13. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M and Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. PLoS Negl Trop Dis 2013; 7: e2195
14. Parmar MKB, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
15. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH and Danenberg PV. Osteopontin but not Osteonectin Messenger RNA Expression is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer. Clin Cancer Res 2004; 10: 1588-1596.
16. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008; 26: 4771-4776.
17. Isa SI, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K and Mack PC. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004. Thorac Oncol 2009; 4: 1104-1110.
18. Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, Van Der Weide H, Rao B and Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT0057-3040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011; 81: 360-368.
19. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT and Maelandsmo GM. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 2013; 13: 540.
20. Sun BS, Li Y, Zhang ZF, You J and Wang CL. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 2013; 96: 1943-1951.
21. Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Yamada S and Tanaka F. Serum Level of Osteopontin as a Prognostic Factor in Patients Who Underwent Surgical Resection for Non-Small-Cell Lung Cancer. Clin Lung Cancer 2013; 14: 288-294.
22. Ostheimer C, Bache M, Guttler A, Kotzsch M and Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonicanhydrase IX and vascular endothelial growth factor. Strahlenther Onkol 2014; 190: 276-282.
23. Zhang T, Zhang DM, Zhao D, Hou XM and Yang TN. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON 2014; 19: 742-748.
24. Alberg AJ, Brock MV, Ford JG, Samet JM and Spivack SD. Epidemiology of Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013; 143: E1-E29.
25. Rittling SR and Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-1881.
26. Weber GF. The Cancer Biomarker Osteopontin: Combination with Other Markers. Cancer Genomics Proteomics 2011; 8: 263-288.
27. Rangaswami H, Bulbule A and Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16: 79-87.
28. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ and Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 2005; 43: 225-236.
29. Denda S, Reichardt LF and Muller U. Iden-tification of osteopontin as a novel ligand for the integrin alpha 8 beta 1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell 1998; 9: 1425-1435.
30. Chakraborty G, Jain S and Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-161.
31. Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL and Ma SC. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis. Mol Histol 2014; 45: 533-540.